
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals Inc is anticipated to experience significant revenue growth, particularly from its product Khindivi, with projections estimating an increase from $3 million in 2025 to a peak of $28 million by 2030. The company has raised the probability of Khindivi's launch to 100%, coupled with an adjustment for an earlier launch in June 2025 and an increase in expected market penetration from 40% to 60% due to the product's ease of administration. Given the demonstrated strength of management in commercial execution, 2025 is expected to be a pivotal year for revenue inflection for the company.
Bears say
Eton Pharmaceuticals's stock outlook appears negative primarily due to the high discount rate of 11% applied in the financial analysis, which indicates a cautious approach towards the company's future cash flows. Additionally, the modest terminal growth rate of 2% further suggests a limited potential for sustained long-term revenue growth, raising concerns about the company’s ability to meet market expectations. Despite a slight increase in the 12-month price target to $35 per diluted share, the fundamental assumptions reflect a cautious stance that may impact investor confidence moving forward.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares